Tags : KISIMA

Boehringer Ingelheim Acquires AMAL Therapeutics for its KISIMA Immunization Platform

Shots: Boehringer Ingelheim acquires AMAL Therapeutics in all-stock transaction for ~$478.5M. AMAL to get $365.9M including up front, clinical, development, regulatory milestones and $112.6M as commercial milestones The focus of the acquisition is to develop new therapies for gastrointestinal and lung cancers in combination with AMAL’s KISIMA immunization platform and to foster BI’s immuno-oncology portfolio […]Read More